الفهرس 
INFLAMMATORY BOWEL DISEASEOnly 14 pages are availabe for public view
 |  | from | 120 |  |  |
| | | from | 120 | | |
Abstract
Inflammatory bowel disease (IBD) is a broad term that describes inflammation of gastrointestinal tract (GIT). The two most common inflammatory bowel diseases are ulcerative colitis (UC) and Crohn’s disease (CD). The treatment of a patient with inflammatory bowel disease (IBD) can be either medical or surgical or in many patients a combination of both. Glucocorticoids (GCs) are powerful and fast acting anti-inflammatory drugs that have been used as treatment for acute flare ups of IBD. However, inter-individual variability in the response to these agents is frequently observed. Glucocorticoids diffuse freely into cells and bind to an intracellular receptor named human glucocorticoid receptor (hGR). So, the sensitivity to these drugs may depend on the receptor number and affinity or on their availability to the receptors. Polymorphisms in the hGR gene (Bcl1) have been described in different populations and may contribute to the variability in sensitivity to GCs. Therefore, it was hypothesized that Bcl1 gene polymorphism may be related to GCs sensitivity in inflammatory bowel diseased patients.